Mathias Onsrud, Taran P. Hellebust, Claes G. Tropé, and Gunnar B. Kristensen, Norwegian Radium Hospital, Oslo University Hospital; Mathias Onsrud, Milada Cvancarova, Taran P. Hellebust, and Claes G. Tropé, University of Oslo, Oslo; Taran P. Hellebust, Norwegian Radiation Protection Authority, Østerås; and Kristina Lindemann, Akershus University Hospital, Lørenskog, Norway.
J Clin Oncol. 2013 Nov 1;31(31):3951-6. doi: 10.1200/JCO.2013.48.8023. Epub 2013 Sep 9.
This follow-up of a randomized study was conducted to assess the long-term effects of external beam radiation therapy (EBRT) in the adjuvant treatment of early-stage endometrial cancer.
Between 1968 and 1974, 568 patients with stage I endometrial cancer were included. After primary surgery, patients were randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280). Overall survival was analyzed by using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate hazard ratios (HRs) with 95% CIs. We also conducted analyses stratified by age groups.
After median 20.5 years (range, 0 to 43.4 years) of follow-up, no statistically significant difference was revealed in overall survival (P = .186) between treatment groups. However, women younger than age 60 years had significantly higher mortality rates after EBRT (HR, 1.36; 95% CI, 1.06 to 1.76) than the control group. The risk of secondary cancer increased after EBRT, especially in women younger than age 60 years (HR, 2.02; 95% CI, 1.30 to 3.15).
We observed no survival benefit of external pelvic radiation in early-stage endometrial carcinoma. In women younger than age 60 years, pelvic radiation decreased survival and increased the risk of secondary cancer. Adjuvant EBRT should be used with caution, especially in women with a long life expectancy.
本研究为一项随机研究的随访,旨在评估外照射放疗(EBRT)在早期子宫内膜癌辅助治疗中的长期疗效。
1968 年至 1974 年间,纳入了 568 例 I 期子宫内膜癌患者。在初次手术后,患者被随机分为阴道镭近距离放疗联合 EBRT(n = 288)组或单纯镭近距离放疗(n = 280)组。采用 Kaplan-Meier 法分析总生存率。采用 Cox 比例风险模型估计危险比(HR)及其 95%置信区间(CI)。我们还按年龄组进行了分层分析。
中位随访 20.5 年(范围,0 至 43.4 年)后,两组患者的总生存率无统计学差异(P =.186)。然而,年龄小于 60 岁的女性在接受 EBRT 后死亡率显著升高(HR,1.36;95%CI,1.06 至 1.76)。EBRT 后继发性癌症的风险增加,尤其是年龄小于 60 岁的女性(HR,2.02;95%CI,1.30 至 3.15)。
我们未观察到早期子宫内膜癌患者接受盆腔外照射放疗有生存获益。对于年龄小于 60 岁的女性,盆腔放疗降低了生存率并增加了继发性癌症的风险。辅助 EBRT 的应用应慎重,特别是对于预期寿命较长的患者。